Selexis CHO Cells in Suspension-1

Company History

Our journey began in 2001 when our Company was formed behind an ambitious vision: to change how biologic drugs are developed.

We’re very proud of what we have accomplished during the past 20 years in translating basic gene expression technologies into a unique platform that is used by more than 100 leading companies worldwide.



Best Workplace in Switzerland by Great Placed to Work® for fourth consecutive year

Names New Chief Business Officer



Best Workplace in Switzerland by Great Placed to Work® for third consecutive year

Names New Chief Executive Officer

Expands scientific and operational leadership teams



Named among “Best Workplaces in Switzerland” for second consecutive year

Fifth SUREtechnology Platform™-generated product receives market approval

Biosimilar becomes sixth SUREtechnology Platform™-generated marketed product



Names Chief Financial Officer

Achieves 100th commercial license agreement

Invests $2 million in state-of-the art laboratory equipment; expands workforce

Swiss Biotech Association honors Selexis among inaugural Swiss Biotech Success Stories

Earns “Best Companies to Work for in Switzerland 2018” certification

Collaborates with Berkeley Lights to accelerate cell line development with Beacon® optofluidic platform

KBI Biopharma Inc. and Selexis form joint Scientific Advisory Board



Opens new world-class laboratory facility and corporate headquarters in Geneva, Switzerland

Acquired by JSR Life Sciences



First Selexis SUREtechnology-generated therapeutic monoclonal antibody approved

Uses next-generation sequencing to fully sequence Selexis-generated research cell banks



Launches SURE CHO-Mplus Libraries™

Sells potential milestone and royalty payments to Ligand Pharmaceuticals



Doubles cell line development laboratory space in Geneva, Switzerland

Completes sequencing of the Selexis SURE CHO-M genome along with scientists at University of Lausanne

Celebrates 10-year anniversary

Launches SUREvariant Screening™

Forms Scientific Advisory Board headed by Sir Gregory Paul Winter, CBE, FRS, FMed Sci



Expands European production and business operations with new facilities and staff

Establishes U.S. subsidiary, Selexis, Inc.



Opens new R&D facility in Plan-les-Ouates, Switzerland



Dr. Fisch wins New Entrepreneurs for Technology and Sciences (NETS) Best Prize



Company co-founded by Dr. Fisch and Prof. Nicolas Mermod, Ph.D., using winning funds from De Vigier Prize



Igor Fisch, Ph.D., wins the De Vigier Prize for the best biotech idea of Y2K